Cobitolimod
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.
Learn moreCalender
- 24 April 2018Annual Report 2017
- 25 April 2018Capital Markets Day
- 17 May 2018Interim Report Q1 2018
- 24 May 2018Annual General Meeting 2018
- 28 August 2018Interim Report Q2 2018
- 19 November 2018Interim Report Q3 2018
